PACKAGE INSERT TEMPLATE FOR PARACETAMOL SUPPOSITORIES

Similar documents
Molecular formula: Molecular weight: C 8 H 9 NO 2 CAS Registry no.:

Metabolism Paracetamol is metabolised in the liver and excreted in the urine mainly as glucuronide and sulphate conjugates.

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

2. QUALITATIVE AND QUANTITATIVE COMPOSITION. Each capsule contains PARACETAMOL 500mg For a full list of excipients, see section 6.1.

Summary of Product Characteristics

CHILDREN S PANADOL COLOURFREE SUSPENSION PANADOL SUPPOSITORIES 125 MG PANADOL SUPPOSITORIES 250 MG DATA SHEET. Proprietary (Trade) Name: PANADOL

Panadeine Tablet, Caplets and Rapid Soluble tablets PRODUCT INFORMATION

NEW ZEALAND DATASHEET

PRODUCT INFORMATION Panadeine EXTRA

Farmadol. Paracetamol 10 mg/ml INFUSION SOLUTION

PANADOL COLD & FLU MAX HOT LEMON Powder for Oral Solution DATA SHEET

DATA SHEET. PANADOL Mini Caps Capsule shaped tablet with a gelatin coating which is one half green and the other half white.

Summary of Product Characteristics

NEW ZEALAND DATA SHEET

PRODUCT INFORMATION CODAPANE XTRA Paracetamol 500 mg and Codeine Phosphate 15 mg Tablets

PRODUCT INFORMATION PANADOL COLD & FLU MAX HOT LEMON POWDER NAME OF THE MEDICINE. Chemical structure: CAS 2 Registry Number: DESCRIPTION

SCHEDULING STATUS: S0 For pack sizes of 24 tablets or less. For pack sizes of more than 24 tablets

PRODUCT INFORMATION. (RS)-N,N-Dimethyl-2-[(2-methylphenyl)phenylmethoxy]ethanamine dihydrogen 2-hydroxypropane-1,2,3-tricarboxylate

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

PARACOD Tablets (Paracetamol + Codeine phosphate)

PANADOL EXTRA PRODUCT INFORMATION

PRODUCT INFORMATION PANADOL TABLETS PANADOL MINI CAPS PANADOL SUPPOSITORIES

PACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP

PIL. ParaCet Flu 500 mg+250 mg/sachet Powder for oral solution paracetamol + ascorbic acid

Levocetirizine dihydrochloride

AUSTRALIAN PRODUCT INFORMATION PANADOL OPTIZORB TABLETS (PARACETAMOL) TABLETS PANADOL OPTIZORB CAPLETS (PARACETAMOL) TABLETS

NOTOPAIN CAPLETS. Diclofenac Sodium + Paracetamol. Composition. Each tablet contains: Diclofenac Sodium BP 50mg Paracetamol BP 500mg.

Summary of Product Characteristics

PRODUCT INFORMATION LEAFLET

PANADOL OSTEO PRODUCT INFORMATION

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory CALPOL TABLETS / SUSPENSION / PAEDIATRIC DROPS

DOMCET Tablet / Suspension (Domperidone maleate + Paracetamol)

SUMMARY OF PRODUCT CHARACTERISTICS

ACETYLCYSTEINE INJECTION

Evolution continues. Year: 1940 Fuel: Electricity Speed: 32 km/h. Year: 1998 Fuel: Electricity Speed: 118 km/h

Package Insert. Elkar

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

PRODUCT INFORMATION ANAGRAINE. Each ANAGRAINE tablet contains 5 mg metoclopramide and 500 mg paracetamol.

Each 5ml of Sinarest LP New Syrup contains: Phenylephrine

SUMMARY OF PRODUCT CHARACTERISTICS 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

DATA SHEET. Paracetamol (BP) 500 mg and Phenylephrine Hydrochloride (BP) 5 mg

NEW ZEALAND DATA SHEET

SUMMARY OF PRODUCT CHARACTERISTICS. Each ml of solution for infusion contains 10 mg of paracetamol.

SUMMARY OF PRODUCT CHARACTERISTICS

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Protamine sulphate LEO Pharma 1400 anti-heparin IU/ml solution for injection and infusion.

SUMMARY OF PRODUCT CHARACTERISTICS

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS

M0BCore Safety Profile

Composition: Each tablet contain. Levocetirizine. Each 5ml contains. Montelukast. Pharmacokinetic properties:

NEW ZEALAND DATA SHEET ACUPAN TM. 3. PHARMACEUTICAL FORM White, round, biconvex, film-coated tablets (7 mm diameter) engraved APN on one face.

Active ingredients: Metoclopramide Hydrochloride mg Equivalent to metoclopramide hydrochloride anhydrous mg

NEW ZEALAND DATA SHEET

SUMMARY OF PRODUCT CHARACTERISTICS

KELFER Capsules (Deferiprone)

KELFER Deferiprone. COMPOSITION KELFER-250 Capsules Each capsule contains Deferiprone 250 mg

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS

Salapin: Salbutamol BP 2mg as sulphate in each 5mL of a raspberry cola flavoured, sugar free syrup.

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Emergency contraception is an occasional method. It should in no instance replace a regular contraceptive method.

Patient leaflet: Information for the user. Paracetamol Galpharm 500mg tablets paracetamol

SUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

PARACIP Injection (Paracetamol )

Nevirapine 200mg Tablet WHOPAR part 4 May 2005 Section 7 updated: May 2016 SUMMARY OF PRODUCT CHARACTERISTICS

MESALO Foam (Mesalazine)

MESULID 100 REVISED PRODUCT INFORMATION

LEAFLET: INFORMATION FOR THE USER. Freshalgin 500th mg tablets Metamizole sodium (M etamizol sodium)

Immodium / loprarmide

PRODUCT INFORMATION. Active ingredients Chemical structure CAS Registry Number. Paracetamol

PROFESSIONAL INFORMATION

Package leaflet: Information for the user. Therimin Skogsbär 500 mg Powder for Oral Solution Paracetamol

SUMMARY OF PRODUCT CHARACTERISTICS

DATA SHEET. Product Summary. 1. Trade Name of Medicinal Product. Protamine Sulphate Injection BP. 2. Qualitative and Quantitative Composition

PRODUCT INFORMATION PANADEINE FORTE

Cetirizine Proposed Core Safety Profile

Orgalutran 0.25 mg/0.5 ml solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

PRODUCT INFORMATION. Active ingredients Chemical structure CAS Registry Number. Paracetamol

Package Insert. Cognitin

Body weight more than 30kg : 10ml (10mg) of the syrup once daily.

Package leaflet: Information for the user. Paralink 10 mg/ml Solution for Infusion Paracetamol

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Mucomist Respirator Solution, Acetylcysteine USP 200 mg/ ml Solution for inhalation (not for injection)

What does this PIL contain?

Konakion MM. Phytomenadione Composition. Properties and effects. Pharmacokinetics

Action Rufenal contains a non - steroidal compound with pronounced antirheumatic, anti-inflammatory, analgesic and antipyretic properties.

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Active ingredients: Paracetamol Codeine phosphate. Chemical names: N-(4-Hydroxyphenyl)acetamide 4,5a-epoxy-3-methoxy-17-methyl-7,8-

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) CORE SPC FOR HUMAN TETANUS IMMUNOGLOBULIN FOR INTRAMUSCULAR USE (CPMP/BPWG/3730/02)

ROSOBAC-1GM / ROSOBAC-FORT

PRODUCT INFORMATION PRODEINE 15 H 3 CO. Paracetamol MW Codeine phosphate MW

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS

TRAPADOL INJECTION FOR I.V./I.M. USE ONLY

INDICATIONS ACULAR 0,4% ophthalmic solution is indicated for the reduction of ocular pain and burning/stinging following corneal refractive surgery.

Transcription:

PACKAGE INSERT TEMPLATE FOR PARACETAMOL SUPPOSITORIES Brand or Product Name [Product name] Suppositories mg Name and Strength of Active Substance(s) Eg Paracetamol 500mg Paracetamol 250mg Paracetamol 125mg Product Description [Visual description of the appearance of the product (colour, odour,superficial markings, shape) eg A white to off-white spindle shaped suppository Pharmacodynamics Paracetamol is a centrally acting analgesic and antipyretic with minimal anti-inflammatory properties. Analgesic The mechanism of analgesic action has not been fully determined. Paracetamol may act predominantly by inhibiting prostaglandin synthesis in the central nervous system (specifically cyclooxygenase (COX)-2) and, to a lesser extent, through a peripheral action by blocking painimpulse generation. The peripheral action may also be due to inhibition of prostaglandin synthesis or to inhibition of the synthesis or actions of other substances that sensitize pain receptors to mechanical or chemical stimulation Antipyretic Paracetamol act centrally on the hypothalamic heat-regulating center to produce peripheral vasodilatation resulting in increase blood flow through the skin, sweating and heat loss. Paracetamol reduces fever by inhibiting the formulation and release of prostaglandins in the CNS and by inhibiting endogenous pyrogens at the hypothalamic thermoregulator center Pharmacokinetics The absorption after rectal administration is found to be erratic and prolonged, varying with the suppository size, composition of its base, rate of dissolution, position in the rectum, and the 1

rectal contents. Peak plasma concentrations occur about 2 to 3 hours after rectal administration. The plasma half life is about 2 hours. Paracetamol is metabolized by the microsomal enzyme system of the liver. This metabolism is mainly to the glucuronide and sulphate conjugates, accounting for approximately 49% and 26% of the ingested dose respectively. About 4% is excreted as free paracetamol. Other minor pathways include the production of catechol derivatives and cysteine conjugates (via glutathione). Paracetamol excretion is rapid and occurs via the urine. Indication Indicated for the relief of fever, headache and symptoms of cold and flu, toothache, discomfort of teething and fever after vaccination. Recommended Dosage Adult and Children above 12 years: 500mg to 1 g every 4 to 6 hours, up to 4 times daily. Paediatric It is more accurate to use the body weight of the child to calculate the correct dose in paediatrics. Calculation is based on recommended dose of 10 to 15 mg/kg/dose ORALLY every 4 to 6 hours Note: 1kg = 2.2lb Rectal doses, which may be given to children every 4 to 6 hours if necessary, up to 4 times daily are: Infants under 3 months: as instructed by physician 3 months to 1 year: 60 to 125 mg 1 to 5 years: 125 to 250 mg 6 to 12 years: 250 to 500 mg Rectal doses in younger children: neonates 28 to 32 weeks postmenstrual age: 20 mg/kg as a single dose then 15 mg/kg every 12 hours if necessary to a maximum of 30 mg/kg daily neonates over 32 weeks postmenstrual age: 30 mg/kg as a single dose then 20 mg/kg every 8 2

hours if necessary to a maximum of 60 mg/kg daily 1 to 3 months of age: 30 to 60 mg every 8 hours if necessary Higher rectal doses for use in children with more severe symptoms: 1 to 3 months: 30 mg/kg as a single dose followed by 15 to 20 mg/kg every 6 to 8 hours to a maximum of 60 mg/kg daily older children: 30 to 40 mg/kg as a single dose followed by 15 to 20 mg/kg every 6 to 8 hours to a maximum of 90 mg/kg daily. Usual adult maximum single and daily doses should not be exceeded To be inserted deep into rectum Mode of Administration Rectal Contraindications Hypersensitivity to paracetamol or any of the other ingredients/components of the product. Severe and active hepatic impairment Warnings and Precautions [Specific package insert requirement for paracetamol] Keep out of reach of children. Do not take if allergic to paracetamol. Patients should contact their health care provider if symptoms persist (if the pain lasts for more than 10 days, if there is redness or fever lasts more than 3 days). Paracetamol should be given with care to patients with impaired kidney or liver function. Large doses should be avoided in patients with hepatic impairment. Paracetamol overdose may harm the liver. Do not exceed recommended dose. Paracetamol provides symptomatic relief only, additional therapy to treat the cause of the pain or fever should be instituted when necessary. 3

Effects on Ability to Drive and Use Machines It is unlikely to impair a patient s ability to drive or use machinery. Interactions with Other Medicaments The anticoagulant effect of warfarin and other coumarins may be enhanced by prolonged regular daily use of paracetamol with increased risk of bleeding; occasional doses have no significant effect. Statement on Usage During Pregnancy and Lactation Use in pregnancy: Considered to be the analgesic of choice in pregnant patients. Although it crosses placenta, paracetamol is considered to be safe in normal therapeutic doses for short-term use as a minor analgesic/antipyretic in pregnancy. Use in lactation: Excreted in breast milk. Maternal ingestion of paracetamol in normal therapeutic doses does not appear to present a risk to the nursing infant. Adverse Effects / Undesirable Effects Adverse effects of paracetamol are rare and usually mild, although haematological reactions have been reported. Skin rashes and other hypersensitivity reactions occur occasionally. Overdose and Treatment Symptoms: Toxic symptoms include vomiting, abdominal pain, hypotension and sweating. The most serious adverse effect of acute overdose of paracetamol is a dose-dependent, potentially fatal hepatic necrosis. Clinical and laboratory evidence of hepatoxicity may be delayed for up to one week. Major manifestations of liver failure such as jaundice, hypoglycemia and metabolic acidosis may take at least 3 days to develop. Treatment: In cases of overdose, methods of reducing the absorption of ingested drug are important. Gastric lavage is essential even if several hours have elapsed. Prompt administration of 50g activated 4

charcoal and 500ml iced mannitol 20% by mouth, may reduce absorption. If the history suggests that 15g Paracetamol or more has been ingested, administer one of the following antidotes: Acetylcysteine 20% i.v.: Administer intravenously, 20% acetlcysteine (Parvolex, Glaxo) immediately without waiting for positive urine test or plasma level results: initial dose of 150mg/kg over 15 minutes, followed by continuous infusion of 50mg/kg in 500ml 5% glucose/dextrose over 4 hours and 100mg/kg in 1L 5% glucose/dextrose over 16 hours; or OR Oral Methionine: 2.5g immediately followed by three further doses of 2.5g at four hourly intervals. For a 3 year old child, 1g methionine every four hours for four doses has been used; OR Oral Acetylcysteine 5%: 140mg/kg as a loading dose, then 70mg/kg every 4 hours for a total of 17 maintenance doses. If more than ten hours have elapsed since the overdosage was taken, the antidote may be in ineffective Storage Conditions [Store below C] Dosage Forms and Packaging Available [ Packaging type & pack size ] Name and Address of Manufacturer [ Name & full address of manufacturer ] Name and Address of Marketing Authorization Holder [ Name & full address of marketing authorization holder ] Date of Revision of Package Insert [ day/month/year ] 5